CDKN1B and neuroendocrine neoplasm: Mutations in cyclin-dependent kinase inhibitor, CDKN1B (p27) or loss of CDKN1B expression have been observed in gastroenteropancreatic neuroendocrine tumors (Kim et al., 2014).